Protection of IFNAR (-/-) mice against Bluetongue virus serotype 8, by heterologous (DNA/rMVA) and homologous (rMVA/rMVA) vaccination, expressing outer-capsid protein VP2

The protective efficacy of recombinant vaccines expressing serotype 8 bluetongue virus (BTV-8) capsid proteins was tested in a mouse model. The recombinant vaccines comprised plasmid DNA or Modified Vaccinia Ankara viruses encoding BTV VP2, VP5 or VP7 proteins. These constructs were administered alone or in combination using either a homologous prime boost vaccination regime (rMVA/rMVA) or a heterologous vaccination regime (DNA/rMVA). The DNA/rMVA or rMVA/rMVA prime-boost were administered at a three week interval and all of the animals that received VP2 generated neutralising antibodies. The vaccinated and non-vaccinated-control mice were subsequently challenged with a lethal dose of BTV-8. Mice vaccinated with VP7 alone were not protected. However, mice vaccinated with DNA/rMVA or rMVA/rMVA expressing VP2, VP5 and VP7 or VP2 alone were all protected. © 2013 Jabbar et al.

Saved in:
Bibliographic Details
Main Authors: Jabbar, T. K., Calvo Pinilla, Eva María, Mateos, F., Gubbins, S., Bin-Tarif, A., Bachanek-Bankowska, K., Alpar, O., Ortego Alonso, Francisco Javier, Takamatsu, H. H., Mertens, P. P. C., Castillo-Olivares, J.
Format: artículo biblioteca
Language:English
Published: Public Library of Science 2013
Online Access:http://hdl.handle.net/20.500.12792/2160
http://hdl.handle.net/10261/290243
Tags: Add Tag
No Tags, Be the first to tag this record!